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Abstract
To improve the nuclear-targeted delivery of non-viral vectors, extensive effort has been carried out 
on the development of smart vectors which could overcome multiple barriers. The nuclear 
envelope presents a major barrier to transgene delivery. Viruses are capable of crossing the nuclear 
envelope to efficiently deliver their genome into the nucleus through the specialized protein 
components. However, non-viral vectors are preferred over viral ones because of the safety 
concerns associated with the latter. Non-viral delivery systems have been designed to include 
various types of components to enable nuclear translocation at the periphery of the nucleus. This 
review summarizes the progress of research regarding nuclear transport mechanisms. “Smart” non-
viral vectors that have been modified by peptides and other small molecules are able to facilitate 
the nuclear translocation and enhance the efficacy of gene expression. The resulting technology 
may also enhance delivery of other macromolecules to the nucleus.
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Introduction
Recently, gene therapy has been developed for the treatment of debilitating human disorders, 
including diabetes and various cancers; these therapies can overcome the intrinsic 
disadvantages and serious risks of pharmacological agents. Gene therapy aims to introduce 
novel genes or to repair malfunctioning genes as a means to permanently treat or reverse the 
disorders. The exogenous “good” DNA is used to replace the defective DNA at appropriate 
chromosomal targets, correcting malformations. Cancer therapy is one example of a 
situation in which deleterious mutant alleles are replaced with functional ones [1].
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The therapeutic genes encounter various extracellular and intracellular barriers after they are 
administered in vivo. Plasma membranes are apparent barrier to the cellular uptake of 
therapeutic genes. After endocytosis into the cytoplasm, genes are largely routed to the late 
endosomes and lysosomes and are degraded by acidic hydrolases. The remaining genes are 
able to escape from the hydrolysis in the endosomes and lysosomes and travel through the 
highly concentrated and molecularly crowded cytosol to be delivered into the nucleus. One 
of the major hurdles in this process is successful nuclear transport [2]. Although viral 
vectors can efficiently infect cells, non-viral gene delivery results in only 10–20% of the 
applied dose of plasmid DNA enters the targeted cells and only 1–5% of the applied dose is 
able to enter the nucleus [3]. Therefore, successful gene therapy requires the utilization of 
knowledge gained from the study of nuclear transport of viral DNA in non-viral gene 
delivery systems to conquer the barrier of the nuclear envelope (NE). Transportation through 
the cytoplasm or across the endosomal membrane is a prerequisite for gene transfer [4], 
making it as vital to the success of gene-based therapies as nucleus translocation. Here, we 
reviewed the applications of smart delivery of therapeutic DNA across the nuclear 
membrane. The resulting technology may also profit delivery of other macromolecules to the 
nucleus, such as transcription factors or enzymes, which can be used to safely regulate gene 
expression through alternative mechanisms.
Hindrances to nuclear delivery
Cell evolution and appearance of barriers
Eukaryotic cells have developed sophisticated subcellular structures to ensure 
compartmental functions and genetic diversity, and to protect cells from invasion of 
disadvantageous non-self genes [5]. Meanwhile, cells developed regulated transport 
mechanisms to move nutrients or other substances between the surrounding environment and 
the cell interior. Microbes, such as phages and bacteria, also adapted to invade these cells 
and avoid the barriers created by the developed complexity. Our understanding of these 
invasion and defense mechanisms may facilitate the delivery of therapeutic genes. This 
series of barriers is associated with (1) the stability of DNA and vectors in the extracellular 
environment, (2) cellular uptake by endocytosis, (3) escape from the endo/lysosomes, (4) 
transportation through the cytoplasm, and (5) importation into the nucleus (Figure 1).
Extracellular barriers
Therapeutic genes could be delivered through different administrations, including 
intramuscular or intravenous (IV) injections, and pulmonary or ocular drug delivery (Figure 
1). The genes may encounter many barriers dependent on the administration routes, such as 
blood components, endothelial cells, respiratory mucus, the blood–brain barrier, the blood–
retinal barrier, extreme pH, proteases and nucleases, the immune defenses and scavenger 
systems [6]. Thus, the therapeutic gene must be encapsulated and delivered by a vector to 
the appropriate extracellular location.
Blood is one of the major barriers to an injected gene vector. Various polymers can be used 
to condense DNA and protect it from degradation in the blood. Usually, such polymers have 
an excess of positive charge to enable sufficient compaction of the negatively charged DNA. 
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The resulting complex possesses a net positive surface-charge which might cause self-
aggregation and be disadvantageous when injected into the bloodstream [7]. For instance, 
positively charged complexes can bind to plasma proteins and activate the complement 
system against exogenous material within the bloodstream. Additionally, the complex may 
also be cleared rapidly by the thrombocytes, leukocytes, erythrocytes or other blood 
components. PEGylation, including the conjugation of polyethyleneglycol (PEG) [8] before 
particle formation, covalent grafting of PEG [9] or N-(2-hydroxypropyl)methacrylamide 
(HPMA) [10] after particle formation, or the association of PEG via inclusion complex 
formation with the surface of β-cyclodextrin-containing polyplexes, can increase stability 
against self-aggregation and reduce non-self interactions.
Pulmonary delivery is also an attractive route for gene delivery. Since the cloning of the 
cystic fibrosis (CF) gene (CFTR) in 1989, many clinical trials have been completed, 
demonstrating a proof-of-principle for gene transfer to the airway. However, clinical trials 
suggest that targeted delivery to the lungs is rather difficult. The failure of clinical trails is 
attributed to respiratory mucus, alveolar fluid [11] and the secretions in the fibrotic airway.
Additionally, gene therapy could be an alternative treatment of many retinal disorders which 
cannot be presently remedied effectively [12,13]. Gene delivery to the posterior chamber, 
e.g. retinal tissues and vitreous, via systemic delivery is constrained due to the presence of 
the blood–retinal barrier [14]. Though the topical application may overcome the barrier, this 
method encounters other problems, for instant, the sclera. Intravitreal injection is less 
invasive than sub-retinal injection and is an alternative delivery method. This route of 
administration requires the complexes to travel through the vitreous, a gel-like substance 
containing negative charged glycosaminoglycans (GAGs). Similar to the CF mucus, this 
biopolymer network may cause aggregation and immobilization of the gene complex. 
Sanders et al. [15] reported when moderate amounts of PEG were conjugated onto the 
complex, aggregation in the vitreous could be partially prevented.
Plasma membranes and endocytosis
Due to the negative charge of the plasma membrane, naked DNA, a negatively charged 
macromolecule, does not cross membrane barriers efficiently. DNA has to rely on a vector to 
gain access to individual cells. The positively charged surface of a successful vector interacts 
with the negatively charged cell surface. However, this electrostatic interaction lacks 
specificity unless a specific targeting ligand is incorporated into the vector. Thus, it is 
necessary to preclude such non-specific interactions by reducing the charge ratio of the 
complex, presenting a stealth property [16] or incorporating a specific targeting ligand.
Occasionally, a vector/gene complex can fuse directly with the plasma membrane due to the 
properties of the vector [17] or the incorporation of a cell-penetrating peptide [18]. However, 
most of the time, a complex enters cells through endocytosis. Eukaryotic cells exploit 
various endocytic pathways [19,20], such as clathrin-dependent endocytosis via coated pits, 
and non-clathrin dependent endocytosis including caveolin-mediated endocytosis, clathrin 
and caveolinin-dependent endocytosis, and macropinocytosis. Parts of the caveolar vesicles 
are fused with neutral pH caveosomes, limiting delivery to the lysosomes where intracellular 
vesicles experience acidification and hydrolysis. The clathrin-dependent endocytosis 
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pathway is more efficient in transfection. Several studies of different cell types demonstrate 
that lipoplexes are internalized through clathrin-dependent endocytosis. Polyplexes and/or 
lipoplexes may be internalized by other endocytic mechanisms, for example, a combination 
of clathrin-dependent endocytosis and clathrin-independent endocytosis [21]. Nevertheless, 
inhibition of transfection is seen upon treatment of cells with specific inhibitors of 
endocytosis or overexpression of a dominant negative mutant protein [22], which is 
necessary for the formation of the coated pits.
Lysosomal degradation
Once the intracellular vesicles carrying the vector are taken up via endocytosis, they usually 
fuse with the endocytic compartments. Initially, the vector appears within vesicles known as 
the early endosomes, which are located peripherally in the cell and possess a slightly acidic 
pH. These early endosomes are responsible for either the redistribution of material from or 
the return of internalized material to the cell surface. The late endosomes then traffic the 
vector to the lysosomes where DNA is finally broken-down. Thus, the therapeutic effect of 
DNA is thought to be a consequence of its escape from the endosomal vesicles.
Several mechanisms of escape have been developed, including (a) transbilayer flip-flop of 
anionic lipids from the cytoplasmic face of the endosomal membrane induced by cationic 
lipids [23], (b) charge neutralization of cationic complexing agents with the anionic 
macromolecules of the endo-lysosomes membrane, (c) fusion mediated by cationic lipids 
[24], (d) membrane destabilization [25,26], (e) osmotic swelling of the endosomes, or the 
“proton sponge-mediated escape” [27] and (f) the co-addition or covalent coupling of 
fusogenic [28] or endosome-disruptive molecules [29]. As previously mentioned, complexes 
are often PEGylated to pass through the extracellular compartments more effectively, yet, 
PEGylation may exert an inhibitory effect on endosomal escape. The PEGylation prevents 
close contact between the vector and the membranes of the endocytic compartment, not only 
inhibiting endosomal escape but also cellular uptake. Thus, reversible or exchangeable 
PEGylation [30], which is characterized by the ability to be removed in the endosomal 
compartment, is recommended.
The cytoplasmic sieve
Upon release from the endosomes, nucleic acids in naked form or as complexes must pass 
through the molecularly crowded cytoplasmic space toward the nucleus where transcription 
takes places. Observations of intracellular microinjection have demonstrated that the 
movement of free DNA via diffusion is slow and inefficient. Diffusion is passive and size-
dependent; diffusion of large DNA (>250 bp) in cytoplasm is slowed greatly compared to 
that of smaller DNA. Dauty et al. found that the actin cytoskeleton is the principal 
determinant of size-dependent DNA mobility [31]. Free DNA can also be actively 
transported using the network of microtubules [32]; molecules bearing nuclear localization 
signals (NLSs) are able to proceed along the microtubules in a dynein-dependent manner 
[33]. NLSs are important not only in achieving nuclear import, but also in concentrating 
cargo at the perinuclear region. Since the transport by passive diffusion is usually limited, 
directed transport of the complex by dynein/kinesin coating could be an attractive way to 
transport materials to the cell periphery [34].
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The nuclear transport mechanism
The nucleus is isolated from the cytoplasm by a double membrane known as the NE. The 
NE is punctuated by nuclear pore complexes (NPCs), through which exclusive passage into 
and out of the nucleus proceeds [35]. NPCs have a ring of octagonal spokes, which forms a 
central channel, a nuclear basket on the nucleoplasmic side and a cytoplasmic ring on the 
cytoplasmic side. The three rings float on top of one another while the cytoplasmic ring 
appear to be more weakly connected to the spoke ring than to the nuclear ring. The central 
channel has an inner diameter of 75 nm [36] and each clamp-like spoke is attached to the NE 
at two specific sites. The contact region between the membrane and the spoke ring is a 
porous, sponge-like structure and can be traversed through a channel that is approximately 9 
nm in diameter. Integral, inner-nuclear-membrane proteins might be imported along these 
channels [37].
The spoke ring cavity of NPC is the main passage for nuclear translocation. Although there 
are no distinct structural features of the spoke ring cavity, the channel is filled by a 
meshwork formed by natively unfolded phenylalanine-glycine (PG) domains that form a 
selective, hydrophobic barrier to transport inside the NPC. This barrier is semi-permeable 
and prevents the diffusion of macromolecules. The physical diameter of the barrier is 9 nm, 
the upper limit for passive diffusion. However, during the active transport the channel can 
dilate to 39 nm in diameter, facilitating passage to the nucleus with assistance of NLSs [38]. 
The above results and the AFM image all present NPCs exhibit great plasticity [39]. The 
exceptional structure and mechanical flexibility of NPCs are important in fulfilling their 
function in translocation [40].
Mechanisms in importing of cargos through NPC into the nucleus
The precise mechanism by which the carrier–cargo complex is translocated through the 
NPCs remains controversial [41,42]. The affinity gradient model posits that the cargo 
alternate between repeating FG motifs that increase the affinity closer to the nucleus. The 
Brownian affinity-gate model describes the occurrence of translocation through diffusion 
simulated by the accumulation of macromolecules at the cytoplasmic face of NPC. The 
selected phase model suggests that FG repeats interact with each other to generate a tightly 
cross-linked gel, which only allows passage of macromolecules that can interact with FG 
repeats.
However, it is generally accepted that cargos with classic NLSs are recognized by members 
of the importin (also known as karyopherin) superfamily of cellular nuclear transport 
proteins and are then translocated into the nucleus (Figure 2). There are two main types of 
importin, importin-α and importin-β. The NLS containing cargo can bind either to the 
importin-α subunit of an importin-α/β dimmer [43,44] or directly to the importin-β [45,46] 
without the need of an importin-α adaptor molecule. The importin/cargo complex docks at 
the distal end of the NPCs cytoplasmic filaments and then transfers to the central channel of 
the NPC, translocating to the nucleoplasmic side. The cargo is released to the nuclear 
environment after the nuclear RanGTP binds to importin-β. The importin-α and/or -β 
subunits are then recycled back to the cytoplasm to mediate a new round of nuclear import.
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During the importin-dependent transport, facilitation by cytoskeletal movement relies on 
microtubule and actin [47]. Using microtubule motor proteins for transport through the 
cytoplasm towards the nucleus, it is able to enhance conventional nuclear import [48]. 
Interestingly, association with dynein light chains significantly enhances the function of 
NLS in the cargos [49].
There are also several distinct, alternative pathways for nuclear import, which operate 
through the so-called importin-independent mechanisms. Glyco-dependent nuclear import is 
thought to mediate the nuclear translocation of glycosylated plasmids [50]. These nuclear 
shuttling molecules are proteins of the lectin family and appear to be specific to the type of 
sugar moiety. Another interesting pathway implicates DNA nuclear targeting sequences 
(DTS) in an active, energy-dependent and sequence-specific process. DTS has binding sites 
for specific transcription factors that exist in normal mammalian cells (e.g. AP1 and AP2 
TEF-1). When DTS containing plasmid binds to a transcription factor, the NLS in the 
transcription factor triggers importin-dependent nuclear import. For instance, to enter the 
nucleus of smooth muscle cells, a 176 bp portion of smooth muscle gamma-action (SMGA) 
promoter DTS could enhance plasmid DNA expression in a controlled manner [51].
Nuclear retention, or the binding of NLS-containing cargoes to nuclear/nucleolar 
components, may be another mechanism through which nuclear localization is regulated 
[52]. Some molecules, for instance, the HIV-1 transactivator Tat, the angiogenic factor, 
angiogenin, and interferon-induced transcription factor IFI16, are able to accumulate in the 
nucleus in part due to binding to nuclear/nucleolar components.
Lessons from viruses
Much can be learned from viruses about creating an efficient complex. Viruses gain optimal 
intracellular access and deliver their genome (DNA or RNA) into appropriate subcellular 
compartment (in most cases the nucleus). Cell binding, endocytosis, endosomal escape, 
transport through the cytosol and nuclear import are all crucial steps in the process through 
which viruses infect cells. The viral journey provides insight into the cell’s trafficking 
machinery and can be exploited to improve non-viral gene delivery systems [53].
To infect, viruses must first attach to molecules present on the surface of host cell and 
internalize through an endocytic route or fusion reaction [54]. Adenovirus, a non-enveloped 
DNA virus (60–90 nm) with projecting fibers on the capsid, binds to the constitutive 
androstane receptor (CAR) and recruits integrin for internalization and is internalized 
through receptor-mediated endocytosis. However, herpes simplex virus-1 (HSV-1), an 
enveloped DNA virus, induces a fusion reaction of the viral lipid bilayer membrane with the 
plasma membrane, releasing the capsid in the cytoplasm of the host cells. It seems that the 
vector/gene complexes entering via endocytosis should be a better choice than those that 
fuse with the plasma membrane. Targeting of clathrin-dependent endocytosis can be 
achieved by coupling specific ligands to the gene complex, such as transferrin [55–57] and 
folate [58–60]. Preferably, the size of complex should remain smaller than 200 nm to 
promote clathrin-dependent endocytosis. The stability of the complex is also important to 
successful gene transfection [61].
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Subsequently, the complex needs to escape the endosomal compartment before they merge 
with the destructive lysosomes. Enveloped viruses use fusion proteins to cross the membrane 
barrier [62], while non-enveloped viruses utilize detergent-like mechanisms (membrane 
disruption) [63] or barrel-stave mechanism (pores formation) [64] to escape endosomes. 
These processes are usually assisted by the lowering of the pH in the early and/or late 
endosomes. At a low pH, the predominant envelope glycoprotein in the influenza virus, 
hemagglutinin, is subjected to several conformational changes, leading to the protrusion of a 
hydrophobic spike into the endosomal membrane that initiates membrane fusion. Intrinsic 
protease activity of the viral capsid seems to be essential to proper maturation and 
endosomal escape. The adenovirus penton protein, for instance, becomes endosome-
disruptive at a low pH, allowing the passage of intact virus particles through the endosomal 
membrane and into the cytosol [65]. Retroviruses, which are enveloped RNA viruses, have 
similar, pH-dependent envelope proteins [66]. To avoid rapid endosomal escape, a gene 
complex should possess endosomolytic properties upon the lowering of the endosomal pH. 
The combination of an endosomal escape moiety, including diphtheria toxin translocation 
domain, histidine [67], fusogenic peptides [68] and acid-transforming peptide [69], could 
provide various gene complexes with the ability to escape endosome [70,71]. Preferably, 
endosomal escape should occur close to the nuclear membrane and guarantee the therapeutic 
gene is delivered intact.
Once inside the cytosol, particles are actively transported to the nucleus via microtubules 
using the dynein motor protein. The particles then bind to the cytoplasmic face of the NPC 
and transfer DNA into the nucleus shortly thereafter. In response to changes in pH, reductive 
environment, Ca2+ concentration or enzymatic activity during cytoplasmic trafficking, 
viruses can experience structural changes and expose new layers like NLSs. Typically 
importins recognize viruses through NLSs, dock to the NPC and transport them into the 
nucleus. However, viruses vary considerably in their interactions with the nuclear import 
machinery. Adenoviruses undergo extensive disassembly prior to genome import and herpes 
viruses release their genome into the nucleus without immediate capsid disassembly. 
Parvoviruses cause damage to the NE and import through the resulting breaks [72]. Polyoma 
viruses and lentivirus preintegration complexes are thought to enter nucleus in intact form, 
whereas the corresponding complexes of onco-retroviruses delay until host cells undergo 
mitosis because they cannot infect interphase nuclei. Thus, to enhance intracellular transport, 
complexes should be equipped with ligands that are recognized by the microtubule motor 
protein dynein [73,74], or utilize the endosomal vesicles to release their cargo in the 
perinuclear region.
The coupling of NLSs to plasmid DNA has been an attractive strategy in nuclear targeting. 
Another method is through the incorporation of the particles into the nucleus during cell 
division or the trigging of the release of nucleic acids upon cell division. From this point of 
view, an intriguing protein, C-myc, remains attached to the microtubules when the cells are 
in rest but dissociates from the microtubules upon a trigger received during cell division 
[75].
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Application of nuclear targeting
The nucleus presents a major barrier for the delivery of therapeutic genes, thus synthetic 
vectors are extremely inefficient in terms of the exogenous protein production per plasmid 
copy. A surge of research effort has been directed towards facilitating nuclear targeting of 
therapeutic genes or other macromolecules employing various functional peptides and small 
molecules including inorganic and organic molecules.
Peptide-guided nuclear transport
Non-viral vectors must overcome several barriers to achieve successful gene delivery, such 
as condensing and protecting DNA, targeting specific types of cells, disrupting the 
endosomal membrane and delivering DNA to the nucleus [76]. Peptides-based vectors are 
able to more easily achieve nuclear delivery, giving them an advantage over other non-viral 
vectors. For example, cationic peptides can interact with the negatively charged DNA 
through electrostatic interactions resulting in the formation of nanometer-sized particles with 
a net positive charge. These particles can interact with the cell membrane, internalizing into 
the cell to achieve gene expression [77,78].
Poly-L-lysine (PLL) is one of the first cationic peptides used to condense DNA. PLLs of a 
higher molecule weight have a greater net positive charge; they can better bind to DNA and 
form more stable complexes than PLLs of low molecule weight. However, as the length of 
the PLL increase, so does the cytotoxicity [79]. Additionally, although the combination of 
PLLs and the endosomolytic agents, such as chloroquine, will improve transfection 
efficiency, it also induces the cytotoxicity [80]. Many researchers have developed 
homogenous, polylysine-containing peptides. Oligolysine peptides can offer many 
advantages over PLLs, such as low toxicity, precise control of synthesis and site-specific 
attachment of ligands for cell targeting [81–83]. In addition, peptides must have the ability 
to escape the endosome to successfully deliver the cargo to the nucleus. In the endosome, 
some peptides (e.g. histidine-rich peptides) can serve as buffers against the proton pump to 
cause lysis or fusion with the endosomal membrane leading to pore formation. For example, 
histidine can become protonated in the acidic environment of the endosome because the 
imidazole group has a pKa of ~ 6.0 [79].
Fusogenic peptides—Many fusogenic peptides have been utilized to deliver DNA into 
the nucleus. They may also facilitate the delivery into the cytosol and promote endosomal 
escape. Some cell penetrating proteins (CPPs) derived from the transduction domains of 
proteins can interact with cell membranes. TAT peptide (TATp), melittin, transportan and 
penetratin peptides are some examples of CPPs that can interact in this manner. 
Furthermore, there are also several synthetic amphipathic peptides such as GALA 
(Sequence: WEAALAEALAEALAE HLAEALAEALEALAA) and KALA (Sequence: 
WEAKLAK ALAKALAKHLAKALAKALKACEA) that can traverse membranes [79].
TATp is one of the most frequently used CPPs and is derived from the transcriptional 
activator protein encoded by human immunodeficiency virus type 1 (HIV-1). Some studies 
have shown that the cellular penetration of TATp was via a receptor- and endocytosis-
independent mechanism; however, recent studies have concluded that an endocytotic 
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mechanism may be involved. Many TATps have been shown to translocate into the interior 
of various cell types [84]. Cardarelli et al. demonstrated that in the absence of competitors 
(i.e. intracellular cytosolic and nuclear factors) TATRRR (47YGRKKRRQRRR57) binds to 
importin-α and importin-β in vitro. While in live cells, the mutated TATGGG 
(47YGRKKRRQGGG57) is a direct target of both importin-α and importin-β. These nuclear 
properties of TAT can provide the basic knowledge for the rational design of localization 
sequence that is better tailored for nuclear import [85]. Following this rationale, de la Fuente 
et al. prepared stable and water-soluble, gold nanoparticles functionalized with a TAT-
derived peptide sequence (GRKKRRQRRR). This functionalization has allowed the 
nanoparticles to penetrate the cell membrane and accumulate in the nucleus of human 
fibroblast cell lines in vitro [86].
GALA is a 30 amino acid synthetic peptide with a glutamic acid-alanine-leucine-alanine 
(EALA) repeat that also contains a histidine and tryptophan residue. Glutamic acid (Glu) 
was selected to provide the peptide with a pH-dependent, negatively-charged side-chain. As 
pH reduces from 7.0 to 5.0, GALA converts to an amphipathic α-helix from its normal state 
as a random coil. When the peptide is an α-helix, the EALA repeat is adjusted so that the 
peptide would have a hydrophobic face of sufficient hydrophobicity to interact with the lipid 
bilayer. Therefore, in the acidic endosomal environment, GALA is able to bind to bilayer 
membranes and induces leakage from phosphatidylcholine vesicles [79,87]. KALA peptide 
is the result of the replacement of some alanines with lysines and a reduction in glutamic 
acid content. KALA peptide can not only condense DNA, but can also induce membrane 
leakage. As pH decreased, KALA peptide can also converts into an α-helix from its usual 
shape as a random coil, and it is in this way that the peptide induces membrane leakage [79]. 
A multifunctional delivery system for recombinant genes was developed to achieve targeted 
gene delivery to ZR-75-1 breast cancer cells. This system used histone H1 as a condenser, 
KALA to destabilize the endosomal membrane, a cell targeting peptide and an NLS. This 
resulting recombinant vector can successfully disrupt endosomal membranes and reach cell 
nuclei [88].
Nuclear localization signals—To achieve nuclear targeting, many NLSs have been 
developed to assist the DNA to target the nucleus and allow DNA entry through the NPCs by 
active transport. As mentioned, DNA–NLS complexes can be recognized by specific 
intracellular receptor proteins as a nuclear import. Yi et al. have demonstrated that addition 
of NLSs increased the luciferase reporter gene expression by about 200-fold and did not 
induce any apparent cytotoxicity in both HeLa and Cos7 cell lines [89].
Classical NLSs are characterized by short stretches of basic amino acids. The best 
understood examples are those that are similar to SV40 Tag. Other classical NLSs include 
bipartite NLSs that resemble Xenopus protein nucleoplasmin and NLSs that are derived 
from yeast homeodomain contain protein MATα2 and are composed of charged/polar 
residues interspersed with non-polar residues. Non-classic NLSs lack the stretches of basic 
amino acids. The well-known example is the hydrophobic, 38-residue M9 sequence of the 
human mRNA-binding protein hnRNP A1. Novel classes of importin α-dependent NLSs 
emerge through high throughput screening of random peptide libraries [90]. Through amino 
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acid replacement we can generate more unconventional classes of NLSs, such as redox-
sensitive NLSs [91].
If the NLS have a sufficient net-positive charge, they can interact with negatively charged 
DNA to enhance the nuclear targeting with or without the presence of another condensing 
agent. However, in this way, NLSs probably dissociate from DNA before they have reached 
the nucleus. NLSs may also be associated with DNA with a chemical group or site-specific 
attachment using a peptide-nucleic acid (PNA) clamp. If the NLS peptides covalently attach 
to the DNA through chemical groups, NLS peptides may occur at any location of the DNA, 
including the gene of interest, which may lead to the inhibition of gene expression [79]. To 
avoid these issues, PNA clamps can be used for specific attachment of the NLS sequence to 
plasmid DNA. Bremner et al. increased seven-fold in gene expression by using a NLS 
peptide/DNA conjugate formed by site-specific linkage of an extended SV40 peptide via a 
PNA clamp [92].
DNA binding proteins—DNA binding proteins (DBPs) are capable of binding DNA and 
have been exploited as DNA carriers in gene delivery. Full-length proteins or protein 
fragments of significant size protect NLSs from unwanted non-specific interaction with the 
phosphate groups in DNA. Furthermore, these proteins keep the NLSs in appropriate, 
tertiary structure to promote strong binding to the relevant, nuclear transport proteins. The 
use of such proteins has been investigated for several years, such as transcription factors, 
High mobility group (HMG)-box proteins or histones.
Inducible transcription factor nuclear factor (NF)-κB, which contains an NLS sequence, 
could be transported into the nucleus in an importin-dependent fashion and function as a 
transcriptional enhancer, resulting in a 31-fold augmentation of gene expression in 
mammalian cells. In addition, Adi Mesika found that coupling NF-κB p50 with pDNA not 
only facilitated nuclear entry of the DNA but also its migration through the cytoplasm 
toward the nucleus [33]. HMG proteins can bind to DNA in a site-specific or non-specific 
fashion. HMG box 1 (HMGB1) is an abundant nuclear protein that binds to double-stranded 
DNA. HMGB1 is composed of HMG box A, box B and C-terminal acidic regions. 
Condensation of DNA by HMG-1 is sufficient to promote efficient gene transfer, while 
recombinant, TAT-linked HMGB1 box A (rTAT-HMGB1A) had a higher efficiency of gene 
transfer and no cytotoxicity to HEK293 cells [93]. The pre-requisite of being an efficient 
DNA carrier is that the DNA binding and importin recognition properties of these proteins 
are not mutually exclusive. A study regarding the ability of core histone H2B derivatives to 
mediate gene delivery showed histones have significant capability of importin binding and 
nuclear targeting. Coupled with their DNA binding abilities of histones, these capabilities 
make them interesting prospects for use as a gene delivery vehicle [94]. Gene expression 
induced by histones is tested using either H2B monomeric protein or heterodimeric form 
with histone H2A and found H2A/H2B/DNA complexes are able to transfect cells more 
efficiently than LipofectamineTM. Since the nuclear targeting and DNA binding properties 
of histone proteins are independent and they contain protein transduction domains (PTD), 
which enable them to enter intact cells in energy- and receptor-independent fashion, histones 
are well suited for gene transfer application [95].
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Peptide/small molecule-modified pharmaceutical nanoparticles for nuclear-targeted 
delivery
The intracellular delivery of non-viral vectors is inefficient because they are required to 
overcome many barriers inside the cells. To achieve successful nuclear transport, a large 
number of studies have focused on introduction of various peptides or small molecules to 
pharmaceutical nanoparticles both in vitro and in vivo (Table 1).
TATp-modified pharmaceutical nanoparticles—Nanoparticles delivering different 
kinds of cargo, such as DNA and siRNA both in vitro and in vivo can be modified with 
TATp. Josephson et al. reported that TATp was conjugated to a dextran-coated, super-
paramagnetic, iron oxide particle with a mean particle size of 41 nm and an average of 6.7 
TATp conjugates per particle [96]. The transfection efficiency of the modified particles was 
enhanced over 100-fold from that of un-modified particles. NMR imaging detected that 
labeled cells are highly magnetic and could be retained on magnetic separation columns. 
Therefore, this method serves a tool for magnetic resonance imaging (MRI) or magnetic 
separation of homed cells in vivo. Furthermore, 4% of magnetically labeled CD34+ cells 
homed to bone marrow per gram of tissue and magnetically labeled cells that had homed to 
bone marrow could be recovered by using a magnetic separation column [97].
TATp can also be applied to the intracellular delivery of lipid-based gene carriers. Torchilin 
et al. have developed 200 nm liposomes that are attached by TATp and can be delivered into 
cells. The intracellular localization of fluorescent TATp-modified liposomes can be observed 
in Lewis lung carcinoma cells of mice, BT20 tumor cells of the human breast, and H9C2 
cardiac myocytes of rats. Later, they designed TATp liposomes containing a cationic lipid 
(DOTAP) formed firm non-covalent complexes with DNA [98,99]. Following intratumoral 
injection of pEGFP-N1 plasmid encoding for the green fluorescent protein (GFP) formulated 
with TATp-liposomes, expression of GFP was observed in the tumor cells. Moreover, these 
liposomes enhanced the delivery of pEGFP-N1 plasmid to human brain tumor U-87 MG 
cells both in vivo and in vitro [100]. Rudolph et al. have discovered that incorporation of a 
dimeric, HIV-1 TATp into SLN gene vectors also significantly enhanced gene expression 
both in vitro and in vivo [101]. To improve the biocompatibility, thiocholesterol-based 
cationic lipids (TCL) have been designed, which can be used to package DNA and protect it 
from DNase digestion. When TATp (GRKKRRQRRRGYG) was incorporated onto the 
particle surface, the particle-cell recognition was increased and transfection efficiency was 
enhanced 80-fold [102].
TATp was also covalently coupled to 25 kDa polyethylenimine (PEI) through a 
heterobifunctional PEG spacer to form a TAT–PEG–PEI conjugate. This conjugate exhibits 
significantly lower toxicity in vitro and higher transfection efficiency in vivo compared to 
the PEI polyplex [103]. Lai et al. have discovered that PEI-β-cyclodextrin conjugated by 
TATp improved the transfection efficiency of PEI-β-CyD in placental mesenchymal stem 
cells (PMSCs) after 48 and 96 h of post-transfection incubation. The viability of PEI-β-
CyD-treated PMSCs was shown to be over 80% after 5 h of treatment and 24 h of post-
treatment incubation [104].
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NLSs-modified pharmaceutical nanoparticles—NLSs can be used to enhance the 
nuclear localization of nonviral vectors. Cationic liposomes composed of DOTAP:DOPE 
(1:1 w/w) that are conjugated with a synthetic NLS peptide derived from the SV40 virus 
could be used to deliver a luciferase-encoding PGL3 plasmid into SKnSH, mammalian 
neuroblastoma cells. The luciferase expression of NLS-modified liposomes was enhanced 
three-fold compared to non-modified cationic liposomes [105]. Tachibana et al. incorporated 
the NLSs of the SV-40 large T-antigen in the fluorescein isothiocyanate (FITC)–bovine 
serum albumin, which were then encapsulated into the pH-sensitive liposomes. In the 
presence of NLSs, FITC-alb was successfully delivered into the nucleus, while no transport 
into nucleus was observed in the absence of NLSs [106]. Yin et al. conjugated NLSs 
(PKKKRKV) with cobalt(II)-polybenzimidazole complex to transfer genes in both normal 
and cancer cell lines [107]. The NLS-modified Co(II) complexes could condense more DNA 
than that in the absence of NLS. NLSs-bound condensates showed five-fold enhanced 
transfection efficacy in different cell types and lower cytotoxicity than NLS-free ones. In 
addition, NLSs and other functional peptides and/or small molecules can be applied 
simultaneously to increase the nuclear import. Moore et al. have investigated the coupling of 
one SV-40 peptide (a classical NLSs) or two TATp (a non-classical NLSs) to PEG-DBP 
vehicles to increase the transfection of PEG-DBP/DNA particles 15-fold. The coupling also 
resulted in efficiency similar to that of a common cationic polymer vehicle, PEI [29].
DNA-binding protein-modified pharmaceutical nanoparticles—An alternative to 
using DNA-binding proteins is to couple the protein to a polycation condensing agent. In 
combination with NF-κB analogs, the transfection of plasmid DNA by PLGA/PEI 
nanospheres in COS7 cells was significantly enhanced due to effective intranuclear transport 
[108]. Natural condensing agents may offer the opportunity to construct more organized and 
therefore more stable complexes. Shen et al. investigated a combined carrier that is 
comprised of PEI and HMG-1. They found the volume of pDNA/HMG-1/PEI complex was 
104–106 times smaller than naked pDNA and the complex presented as homogeneous 
spheres [109]. Transfection efficiencies for pDNA/HMG-1/liner PEI complex and pDNA/
HMG-1/branch PEI complex were 2.9-fold and 4.0-fold greater than that for pDNA/liner 
PEI and pDNA/branch PEI complexes, respectively. HMGB1/PEG-PEI combined vectors 
were used to deliver pDNA [110]. HMGB1 molecules could bind with the pDNA chains but 
does not condense pDNA well. PEG–PEI could further compact pDNA/HMGB1 complex 
into nanosized spherical terplex. HMGB1 in the terplex was able to assist in the 
transportation of pDNA into the nucleus of cells and result in transfection efficiency 2.6–
4.9-fold higher than that of a common cationic polymer PEI 25 kDa.
Small molecule-modified pharmaceutical nanoparticles
Dexamethasone (DEX): A variety of studies have been conducted on the facilitation of 
nuclear translocation by glucocorticoid receptor (GR). GR is constitutively expressed in the 
cytoplasm. Normally, GR binds to the heatshock proteins and remains in its inactive form. 
However, when glucocorticoid enters the cells and binds to GR, the conformation of GR 
changes and the receptor–ligand complex is translocated into the nucleus. Simultaneously, 
NPCs are dilated to approximately 140 nm and the giant pore, 300 nm in diameter, can be 
visualized [111].
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DEX, a potent glucocorticoid, has been conjugated to polymers to improve the nuclear 
transport. Compared to unmodified PEI, DEX-conjugated PEI (2 kDa) of low molecule 
weight, increased the gene expression level by an order of magnitude in HepG2 cells and at 
least two orders for magnitude in 293 cells [112]. The nuclear localization and 
hydrophobicity of DEX contribute to its greater membrane perturbation and increases 
transfection efficiency. Similarly, polyamidoamine(PAMAM)-Dex showed approximately 
two-fold higher transfection efficiency in 293 cells than PAMAM, especially in the presence 
of serum [113]. In the previous studies, the Yao lab has developed a DNA ternary complex 
system of hyaluronic acid (HA)/PEI-DEX/DNA. In this system, PEI1800-DEX is used to 
compact DNA into a nanosized structure and facilitates the nuclear translocation of DNA 
into tumor cells. A polyanion HA was applied to improve targeted delivery to the tumor and 
reduce cytotoxicity. The results demonstrated that, among all complexes that were 
investigated, ternary complexes with ~160 nm in diameter exhibit the lowest cytotoxicity 
and the highest transfection efficiency in B16F10 cells. The ternary complexes can facilitate 
more efficient cellular uptake and nuclear transport of DNA than PEI1800-DEX/DNA binary 
complexes. In addition, ternary complexes of HA/PEI1800-DEX/DNA showed anti-
inflammation activity and greatly suppressed tumor growth in vivo [114,115].
The relationships between structure and transfection activity were investigated using various 
glucocorticoid–PEI conjugates, which employed betamethasone (BET), DEX, 
methylprednisolone (MPL), prednisolone (PNL) and hydrocortisone (HC). The transgene 
expression enhanced linearly with the increasing glucocorticoid potency. The increase in 
transfection capability generally follows the order: HC-PEI<PNL-PEI<MPL-PEI<DEX-
PEI<BET-PEI, with more pronounced enhancement in DEX-PEI and BET-PEI. The 
maximum transfection efficiency mediated by DEX-PEI and BET-PEI was higher than that 
mediated by PEI 25 kDa, even at the best weight ratio, while their cytotoxicities were lower 
than PEI 25 kDa.
All-trans-retinoic acid (ATRA): Similar to the nuclear translocation of DEX-bound GRs, 
ATRA can be translocated into the nucleus via retinoic acid receptors (RARs), which are 
members of the superfamily of nuclear hormone receptors [116]. ATRA binds to specific, 
intracellular, lipid-binding proteins, such as retinoic acid binding proteins (CRABP-I and II) 
and fatty acid binding proteins (FABPs). In cells with high CRABP-II/FABP5 ratios, ATRA 
could function through RAR and implement nuclear import [117]. Researchers synthesized 
PRA in which ATRA was grafted to PEI [118]. The transfection efficiency of PRA/DNA 
complex was comparable to that of PEI/DNA complex in NIH3T3 cells and lower than that 
of PEI/DNA complex in HeLa cells. However, a mixed gene complex of PEI and PRA 
showed two- to four-fold enhancement of transfection efficiency as compared with 
PEI/DNA complex. The hydrophobicity of ATRA leads to its localization in the interior of 
the complex, hindering the accessibility and binding of ATRA to CRABP-II and FABP5. 
ATRA-incorporated, cationic liposome/IL-12 plasmid DNA complex were given 
intravenously in a mouse model of metastatic lung tumor. It prolonged the survival time of 
mice significantly, while cationic liposome/IL-12 plasmid DNA complex without ATRA 
only slightly improved therapeutic efficacy [119].
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Calcium phosphate: Due to the fact that the calcium phosphate (CaP) is biocompatible, 
biodegradable and native to the body, the biomaterial is being considered for use in gene 
delivery to protect and transport cargo into cells, finally, into the nucleus. Moreover, CaP can 
escape the endosome without the assistance of additional compounds such as peptides or 
lysomotropic agents, because it can rapidly dissolve in the acidic environment of the 
endosomes. The rapid dissolution of CaP causes endosome to swell and burst, releasing the 
cargo into the cytoplasm. Taking advantages of this phenomenon, the Huang lab has 
developed several kinds of lipid coated CaP (LCP) nanoparticles formulation for efficient 
delivery of siRNA. The cores of the LCP were biodegradable, nano-sized, calcium-
phosphate precipitate. In vitro, The LCP nanoparticles exhibit three- to four-fold higher 
silencing effects compared to the previously used liposome/polycation/DNA complex. When 
the LCP nanoparticles were modified using anisamide, a sigma receptor ligand, the gene 
silencing effect was approximately 70% and 50% in the cultured tumor cells and a xenograft 
model, respectively. On the other hand, un-targeted NPs induced very little silencing [120]. 
Additionally, after C57BL/6 mice received a single IV injection of antiluciferase siRNA 
(0.12 mg siRNA/kg) that had been formulated in targeted LCP nanoparticles, luciferase 
activity in metastatic B16F10 tumor-loaded lungs decreased by 78%. Targeted LCP 
nanoparticles prolonged the mean survival time of the mice by 27.8% while inducing no 
cytotoxicity at the therapeutic dose [121]. In other studies, an anionic lipid, 
dioleoylphosphatydic acid (DOPA) was used to coat the nano-size CaP cores so that the 
coated cores were soluble in organic solvents. The improvement of siRNA delivery was 40-
fold in vitro and four-fold in vivo compared to that of the lipid/protamine/DNA formulation 
[122]. However, for this delivery system to achieve the greatest results, the delivery of 
therapeutic gene to the nucleus should be enhanced, as the genetic information of the cell 
and the transcription machinery both resides in the nucleus. Ca2+-regulated transport is one 
way of nucleocytoplasmic transportation. The intermediate space between the two bilayers 
of a NE is called the cisterna and this is where Ca2+ is stored and released to regulate the 
passage of molecules through NPC. When Ca2+ is present in the cisterna, the central plug 
lies below the cytoplasmic ring of the NPC and the pores of NPC remain open, allowing 
molecules to diffuse through. However, when inositol triphosphate (InsP3) diffuses into the 
InsP3 receptor on the outer nuclear membrane, Ca2+ will release so that NPC undergoes a 
conformational change, blocking the diffusion of molecules into the nucleus through the 
pores. CaP nanoparticles in the cytosol may have inactivated InsP3 so that the drainage of 
cisternal calcium ions does not occur and the plug of the NPC is “on”. In this circumstance, 
gene–Ca2+ complexes could readily enter into the nucleus through the pores of the NPC. 
Other liposomes or polymers without calcium ions cannot enter the nucleus via calcium-
mediated transport [123]. Bisht et al. have prepared CaP nanoparticles that encapsulate 
plasmid DNA. Studies of these formulations have shown that DNA was completely 
encapsulated in the CaP nanoparticles resulting in protection of the DNA from external 
DNase. Moreover, escape from the endosome, nuclear uptake of the plasmid and subsequent 
expression of the genes has been observed in vitro using confocal microscopy. Thus, these 
CaP nanoparticles can be used as an effective non-viral vector [124]. Multifunctional 
membrane-core nanoparticles, composed of CaP cores, arginine-rich peptides, cationic and 
PEGylated lipid membranes and galactose targeting ligands have been developed by Hu et 
al. [125]. This synthetic vector is the most effective synthetic vectors for nuclear delivery of 
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plasmid DNA and subsequent gene expression in hepatocytes in vivo. The inclusion of such 
peptides in LCP was sufficient to elicit high degrees of nuclear translocation of plasmid 
DNA. Comparing to linear CR8C, monocyclic CR8C significantly enhanced in vivo gene 
expression over 10-fold. Though 100-fold lower in activity than the hydrodynamic injection, 
this formulation presents as a much less invasive alternative [125].
In addition, no immune response or major organ damage was observed after treatment with 
siRNA formulated in targeted LCP nanoparticles [120,121], suggesting that LCP 
formulation was safe and weakly immunogenic for systemic targeted delivery of nucleic 
acids. However, Ca2+ plays an important role in cellular signaling pathway. It was also 
described that modulation of Ca2+ represents a major mechanism in the pathogenesis of 
prelethal cellular reactions to injury as well as to the mechanisms involved in both accidental 
and programmed cell death [126]. Therefore, it should be concerned that the accumulation 
of Ca2+ in cells may increase the risk of cell injury. However, unpublished results from this 
lab indicated that excess Ca2+ was pumped either out of the cells or into the mitochondria, 
keeping the intracellular Ca2+ concentration at a low level.
Application of multifunctional envelope nano device for gene delivery
Non-viral delivery systems must have various functions to enable them to overcome the 
barriers that arise during the delivery of cargo to the nucleus. Systems should target specific, 
cell-surface receptors, condense the cargo to protect it from degradation by DNase, escape 
from the endosomes and be able to achieve nuclear import. The multifunctional envelope 
nano device (MEND) has been developed to achieve all of these goals. MEND consists of a 
polycation that condenses with the nucleic acid and a lipid envelope that can be equipped 
with various functional devices (e.g. targeting ligands, PEG and functional peptides) [127].
A series of octaarginine (R8)-modified MENDs for gene delivery has been developed by 
Khalil et al. [128]. When negatively charged, PLL/DNA particles were coated with egg 
phosphatidylcholine, cholesterol (Chol) and stearyloctaarginine (STR-R8), luciferase 
activity increased by more than two orders of magnitude compared with that induced by 
PLL/DNA particles alone. When particles were coated with 
dioleoylphosphatidylethanolamine (DOPE)/Chol/STR-R8, luciferase activity was about four 
orders of magnitude higher. However, the highest luciferase activity was achieved when 
particles were coated with DOPE/cholesteryl hemisuccinate (CHEMS)/STR-R8. 
Additionally, LacZ plasmid DNA was delivered to the hair follicle cells of four-week-old, 
ICR mice in vivo. This advancement enabled the observation of gene expression in the 
treated cells. The study also elucidated the effects of the delivery of luciferase-encoding 
pDNA and anti-luciferase oligodeoxynucleotide (ODN) in three types of R8-MENDs that 
were condensed with three polycations, STR-R8, PLL and protamine. The ODN-MEND that 
was condensed with protamine achieved a 90% antisense effect 16 h after transfection and a 
persistent antisense effect of over 75% for up to 48 h [129]. Another MEND for targeted 
gene delivery to ZR-75-1 breast cancer cells has been developed by Soltani et al. [88]. This 
system consists of two tandem repeating units of truncated histone H1 to condense pDNA, a 
peptide ligand to target ZR-75-1 cells, KALA to disrupt endosomal membrane and NLS to 
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facilitate pDNA to the nucleus. This vector with four functions achieved a higher gene 
transfection than any vector without functional motifs.
The importance of nuclear gene delivery for gene expression to gene-based therapeutic 
cannot be disputed. Some studies of multifunctional envelope-type nano devices are focused 
on the intracellular disposition rather than nuclear gene delivery. Yamada et al. have 
prepared novel gene delivery vectors by integrating R8-MEND and biocleavable 
polyrotaxanes (dimethylaminoethyl(DMAE)-SS-PRX) as a DNA condenser to improve the 
intranuclear DNA disposition. Surprisingly, the transfection activity of R8-MEND 
containing 29DMAE was almost five-fold greater than that of R8-MEND containing 
protamine. This finding strongly supports the theory that intra-nuclear DNA disposition 
plays a very important role in the gene transfection and expression induced by non-viral 
vectors [130]. Moreover, Akita et al. have developed a tetra-lamellar MEND (T-MEND) that 
is coated with two nuclear membrane-fusogenic, inner envelopes and two endosome-
fusogenic, outer envelopes to overcome the endosomal and nuclear membrane barrier via a 
step-wise fusion process. To access the function of the nucleus-fusogenic lipid, GFP was 
encapsulated into rhodamine-labeled multi-lamellar liposomes and incubated with isolated 
nuclei. GFP was delivered to the interior of the nucleus, whereas the signal of the lipid was 
distributed along the nuclear membrane. T-MENDs can be used to effectively transfected 
into JAWSII cells (non-dividing cells) and the transfection activity significantly increased by 
several hundred-fold compared to that of the conventional MEND. These results suggest T-
MEND efficiently delivered DNA into the nucleus through NE, resulting in great 
improvement of transfection activity [131].
Conclusions
The nucleus is a major barrier to the delivery of therapeutic genes. DNA or other therapeutic 
molecules must enter the nucleus in order to be transcribed for gene expression, integration, 
or replication to take place. A successful gene vector should encapsulate and protect the 
cargo for translocation to nucleus while overcoming the numerous intracellular and 
extracellular barriers present in the delivery process. Much progress in the field is modeled 
after the mechanism of nuclear transport employed by the viruses. The coupling of peptides 
or small molecules has made the non-viral systems for gene delivery more appealing and 
efficient. MENDs can achieve impressive nuclear transport. Hopefully, more intelligent and 
efficient non-viral vectors can be expected in the near future.
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Table 1
Peptides/small molecules-modified nanoparticles for intracellular delivery.
Peptides/small molecules Nano-carriers Cells or animals Effect
TATp Superparamagnetic iron oxide particle 
[96,97]
CD34+ cells For intracellular labeling, MRI, 
magnetic separation of homed 
cells, cell imaging
TATp Liposomes [98–100] Mouse NIH/3T3 fibroblasts, 
human BT20 cells, and rat H9C2, 
U-87 MG cells
To show the potential of TAT-
liposome for intracellular 
delivery, and the intracellular 
gene delivery in vitro and in 
vivo
TATp SLN [101] Bronchial epithelial cells and mice To optimize gene transfer and 
offer the opportunity for further 
studies in large animal models
TATp PEI-PEG conjugate [103] A459 cells and mice A new approach to non-viral 
gene carriers for lung therapy, 
comprising protection for 
plasmid DNA, low toxicity and 
significantly enhanced 
transfection efficiency under in 
vivo conditions
TATp PEI-β-CyD conjugate [104] Placental mesenchymal stem cells 
(PMSCs)
To improve the transfection 
efficiency to PMSCs




To improve the efficiency and 
efficacy of non-viral methods of 
gene therapy
NLS pH sensitive liposome [106] Rat peritoneal macrophages To deliver bovine serum 
albumin into the nucleus
NLS Cobalt(II)-polybenzimidazole [107] Various cell lines To enhance expression of the 
transgenes
DBP (NF-κB) PLGA/PEI nanospheres [108] COS7 cells and human monocyte-
derived dendritic cells
To enhance intracellular 
transport
DBP(HMG-1) Linear PEI and branch PEI-based nano-
particles [109,110]
Mammalian cells To improve their gene transfer 
efficiency by non-viral carriers 
with peptides
DEX PEI-based nanoparticles [112] HepG2 cells, 293 cells To increase the membrane 
perturbation and transfection 
efficiency
DEX HA-PEI [114,115] B16F10 cells and tumor-bearing 
nude mice
For double level targeted gene 
delivery with DNA ternary 
complexes
ATRA PEI [118] NIH3T3 cells, HeLa cells To evaluate the nuclear 
translocation of ATRA-enriched 
nanoparticles
ATRA Cationic liposome [119] A mouse of metastatic lung tumor For lung therapy
CaP Asymmetric liposome with a CaP core 
[120–122]
H460 cells, B16F10 cells and 
mice
To increase the cargo delivery 
and release activity
CR8C Cationic liposomes with a CaP core 
[125]
Mouse liver To deliver pDNA to the nuclei 
of mouse hepatocytes
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